General Information of Drug (ID: DM8R71T)

Drug Name
BL-22 Drug Info
Synonyms CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM8R71T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting B-cell receptor CD22 (CD22)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moxetumomab pasudotox DMN63DZ Hairy cell leukaemia 2A82.2 Approved [3]
Inotuzumab ozogamicin DMAC130 Acute lymphoblastic leukaemia 2A85 Approved [4]
OspA lipoprotein DMF5ZB3 Lyme disease 1C1G Approved [5]
Epratuzumab DMI1ZXV Acute lymphoblastic leukaemia 2A85 Phase 3 [6]
CAR-T cells targeting CD22 DM6XN4C Non-hodgkin lymphoma 2B33.5 Phase 2 [7]
CAR-T cells targeting CD22 DM6XN4C Non-hodgkin lymphoma 2B33.5 Phase 2 [8]
AUTO3 DMC5NSO Acute lymphoblastic leukaemia 2A85 Phase 1/2 [9]
CART-19/22 DMX0R1E leukaemia 2A60-2B33 Phase 1/2 [10]
CD19 and CD22 CAR-T Cells DM581CS B-cell lymphoma 2A86 Phase 1/2 [11]
4SCAR19/22 T cells DMI8TW3 B-cell lymphoma 2A86 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT00924040) Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia. U.S. National Institutes of Health.
2 Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
3 Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
4 Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
5 Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
6 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
7 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
8 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
9 ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
10 ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
11 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
12 ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies